Merck Sharp + Dohme Corp.

Schering Corporation

Opko Health, Inc.

Schering-plough Corporation

Msd Italia S.r.l.

Scherig Corporation

Dong Xiao

Anandan Palani

Neng-Yang Shih

Xianhai Huang

Sunil Paliwal

Cheng Wang

Robert G Aslanian

Shuwen He

Ravi P Nargund

Peng Li

Xing Dai

Michael W Miller

Barbara A Pio

Casey Cameron McComas

Ying Huang

Younong Yu

Pauline C Ting

Christopher W Boyce

Hong Liu

Brian Alexander McKittrick

Amjad Ali

Qun Dang

Kevin D McCormick

Hongjun Zhang

Michael Berlin

Michael Man-Chu Lo

Duane E DeMong

Purakkattle J Biju

Andrew William Stamford

Nigel J Liverton

Tesfaye Biftu

John J Piwinski

David J Blythin

Joey Lee Methot

Phieng Siliphaivanh

Ho-Jane Shue

Robert D Mazzola, Jr

William K Hagmann

Hao Wu

Duane A Burnett

Yongxin Han

Alexander Pasternak

Hubert B Josien

Tao Guo

Elizabeth M Smith

Joseph Michael Kelly

Steven L Colletti

Liangqin Guo

Guoqing Li

Cheng Zhu

Hon-Chung Tsui

Michelle Laci Wrobleski

Gregory A Reichard

Ashwin Umesh Rao

Xiao Chen

Xuanjia Peng

Richard Soll

Harry R Chobanian

Yeon-Hee Lim

Helen Y Chen

Lin Chu

Nicolas Zorn

Jun Qin

Yan Guo

Christopher W Plummer

Rongze Kuang

Linda Brockunier

Junying Zheng

Wei Zhou

Heping Wu

Walter Won

Timothy J Henderson

Qiaolin Deng

Tao Yu

Paul Tempest

Jayaram R Tagat

Clare London

Qin Jiang

Haiqun Tang

Gang Zhou

Tin-Yau Chan

Jing Su

Li Xiao

Rajan Anand

Manuel De Lera Ruiz

Frank Narjes

John P Caldwell

De-Yi Yang

Uwe Koch

Tanweer A Khan

Dane James Clausen

Petr Vachal

Qinglin Pu

Yonglian Zhang

Joel M Harris

Anilkumar G Nair

Joerg Habermann

Chad E Bennett

Feng Ye

Thomas A Bara

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

Antidiabetic spirochroman compounds

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

Disclosed are compounds of Formula G1: where 'R'. 'R' to &#x201c;R&#x201d;, &#x201c;n&#x201d;, &#x201c;m&#x201d;, &#x201c;p&#x201d;, &#x201c;W&#x201d;, &#x201c;X&#x201d;, &#x201c;Y&#x201d;, and &#x201c;Z&#x201d; are defined herein, which compounds are antagonists of Areceptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which Areceptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NKreceptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

A NKantagonist having the formula (I), wherein Arand Arare optionally substituted phenyl or heteroaryl, Xis an ether, thio or imino linkage, Rand Rare not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

Disclosed are compounds of Formula A: (structurally represented) where 'RG1', 'RG2a', &#x201c;RG4&#x201d;, &#x201c;RG5&#x201d;, &#x201c;MG1&#x201d;, &#x201c;n&#x201d; and &#x201c;m&#x201d; are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I) 

Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

Growing community of inventors

Warren, NJ, United States of America

Dong Xiao